Davita (NYSE:DVA) Stock Rating Reaffirmed by SunTrust Banks

SunTrust Banks reissued their hold rating on shares of Davita (NYSE:DVA) in a research report report published on Wednesday, The Fly reports. They currently have a $68.00 price target on the stock.

A number of other research analysts also recently issued reports on DVA. TheStreet upgraded shares of Davita from a c+ rating to a b- rating in a research report on Wednesday, July 24th. UBS Group cut their price objective on shares of Davita from $61.00 to $60.00 and set a neutral rating for the company in a report on Thursday, August 22nd. ValuEngine cut shares of Davita from a hold rating to a sell rating in a report on Tuesday, August 20th. William Blair reaffirmed a buy rating on shares of Davita in a report on Thursday, June 20th. Finally, Robert W. Baird cut shares of Davita from an outperform rating to a neutral rating and cut their price objective for the company from $70.00 to $65.00 in a report on Friday, July 26th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $67.31.

NYSE DVA traded up $0.49 on Wednesday, reaching $60.30. 2,681,741 shares of the company’s stock traded hands, compared to its average volume of 2,201,468. The firm has a market cap of $9.63 billion, a price-to-earnings ratio of 16.89, a P/E/G ratio of 0.58 and a beta of 1.59. The stock has a 50 day moving average price of $58.24 and a 200-day moving average price of $54.37. Davita has a fifty-two week low of $43.40 and a fifty-two week high of $79.11. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.10 and a current ratio of 1.12.



Davita (NYSE:DVA) last posted its earnings results on Thursday, August 1st. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.12. The company had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.05 earnings per share. As a group, equities research analysts anticipate that Davita will post 4.79 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rehmann Capital Advisory Group increased its holdings in Davita by 51.3% in the second quarter. Rehmann Capital Advisory Group now owns 841 shares of the company’s stock valued at $47,000 after buying an additional 285 shares in the last quarter. Boston Partners increased its holdings in Davita by 7.7% in the second quarter. Boston Partners now owns 1,285,276 shares of the company’s stock valued at $72,313,000 after buying an additional 92,244 shares in the last quarter. Atria Investments LLC increased its holdings in Davita by 156.7% in the second quarter. Atria Investments LLC now owns 9,562 shares of the company’s stock valued at $311,000 after buying an additional 5,837 shares in the last quarter. Treasurer of the State of North Carolina increased its holdings in Davita by 8.5% in the second quarter. Treasurer of the State of North Carolina now owns 64,506 shares of the company’s stock valued at $3,629,000 after buying an additional 5,040 shares in the last quarter. Finally, Sage Rhino Capital LLC increased its holdings in Davita by 4.6% in the second quarter. Sage Rhino Capital LLC now owns 14,558 shares of the company’s stock valued at $819,000 after buying an additional 636 shares in the last quarter. 91.47% of the stock is owned by institutional investors.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Recommended Story: What is net income?

The Fly

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.